BioSpace News Archive

InMode Ltd. (Nasdaq: INMD) , a leading global provider of innovative medical technologies, today announced that Yair Malca , Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer, will present in-person at the Barclays Global Health Conference in Miami on March 15, 2023.

Akebia Therapeutics, Inc. today announced plans to release its financial results for the fourth quarter and full-year ended December 30, 2022 on Thursday, March 9.

Silence Therapeutics plc today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2022, on Wednesday, March 15, 2023.

HeartBeam, Inc anywhere, will hold a conference call on Thursday March 16, 2023 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full fiscal year ended December 31, 2022, and will be reviewing recent announcements, ongoing initiatives, and key 2023 milestones.

Vistagen today announced that its Chief Executive Officer, Shawn Singh, will present and host one-on-one meetings at the Cowen 43rd Annual Health Care Conference.

Neuro20 Technologies Corp today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s 510(k) pre-market approval application for its Neuro20 PRO System.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, is showcasing enhancements to its cardiology portfolio at the Annual Scientific Session & Expo of the American College of Cardiology/World Congress of Cardiology event (ACC.23/WCC, March 4 – 6, New Orleans, USA).

Adial Pharmaceuticals, Inc. announced that it will host a conference call and webcast on Tuesday, March 7, 2023, at 8:15 a.m. Eastern Time, to provide an update on its regulatory and partnering strategy for the United States and Europe.

Axis Research & Technologies, a premier bioskills training and cadaver lab supporting medical device research and training, is proud to introduce Dr. Mark G. Freeman as the company’s Chief Medical Advisor.

Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced Part 2 of the evidence-based guidelines series for MicroPulse Transscleral Laser Therapy (TLT) has been published in Clinical Ophthalmology1 by the international consensus panel of ten glaucoma experts.